1-(2-氯乙基)三唑 | 70501-79-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(2-氯乙基)三唑
• 英文名称: 1-(2-Chloroethyl)-1,2,3-triazole
• 英文别名: 1-(2-chloroethyl)triazole；1-(2-chloro-ethyl)-1H-[1,2,3]triazole；1-(2-Chloroethyl)-1H-1,2,3-triazole
• CAS: 70501-79-0
• 化学式: C₄H₆ClN₃
• mdl: MFCD11520930
• 分子量: 131.565
• InChiKey: NHZHGQPHZURUDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-氯乙基)三唑 以62%的产率得到
  参考文献：
  名称：

  VERESHCHAGIN L. I.; TIXONOVA L. G.; MAKSIKOVA A. V.; GAVRILOV L. D.; GARE+, ZH. ORGAN. XIMII, 1979, 15, HO 3, 612-618

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(2-chloro-ethyl)-1H-[1,2,3]triazole-4,5-dicarboxylic acid 以86%的产率得到
  参考文献：
  名称：

  VERESHCHAGIN L. I.; TIXONOVA L. G.; MAKSIKOVA A. V.; GAVRILOV L. D.; GARE+, ZH. ORGAN. XIMII, 1979, 15, HO 3, 612-618

  摘要：

  DOI：

文献信息

• Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-<i>d</i>]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor
  作者：Kazuhiro Miwa、Takenori Hitaka、Takashi Imada、Satoshi Sasaki、Mie Yoshimatsu、Masami Kusaka、Akira Tanaka、Daisuke Nakata、Shuichi Furuya、Satoshi Endo、Kazumasa Hamamura、Tomoyuki Kitazaki

  DOI：10.1021/jm200216q

  日期：2011.7.28

  We previously discovered an orally active human gonadotropin-releasing hormone (GnRH) receptor antagonist, thieno[2,3-d]pyrimidine-2,4-dione derivative 1 (sufugolix). To reduce the cytochrome P450 (CYP) inhibitory activity and improve in vivo GnRH antagonistic activity, further optimization of this scaffold was carried out. We focused our synthetic efforts on chemical modification at the 5 and 3 positions

  我们以前发现了一种口服活性人促性腺激素释放激素（GnRH）受体拮抗剂，thieno [2,3 - d ]嘧啶-2,4-dione衍生物1（sufugolix）。为降低细胞色素P450（CYP）抑制活性并提高体内GnRH拮抗活性，对该支架进行了进一步优化。基于计算模型，我们将合成工作集中在噻吩并[2,3 - d ]嘧啶-2,4-二酮环的5和3位的化学修饰上，从而发现了1- 4- [1 -（2,6-二氟苄基）-5-[（二甲氨基）甲基] -3-（6-甲氧基吡啶并-3-基）-2,4-二氧-1,2,3,4-四氢噻吩并[2,3- d ]嘧啶-6-基]苯基} -3-甲氧基脲（16b）作为高效和口服活性的GnRH拮抗剂。在没有CYP抑制的胎牛血清（FBS）存在下，化合物16b表现出强大的体外GnRH拮抗活性。口服16b维持3 h / kg剂量的去势食蟹猕猴血浆黄体生成激素水平的抑制作用超过24小时。化合
• Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
  申请人：Pfizer Inc

  公开号：US06723719B1

  公开（公告）日：2004-04-20

  Compounds of formulae (IA) and (IB) or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein R1 is C1 to C3 alkyl substituted with C3 to C6 cycloalkyl, CONR5R6 or a N-linked heterocyclic group; (CH2)nHet or (CH2)nAr; R2 is C1 to C6 alkyl; R3 is C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy; R4 is SO2NR7R8; R5 and R6 are each independently selected from H and C1 to C4 alkyl optionally substituted with C1 to C4 alkoxy, or, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group; R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10-piperazinyl group; R10 is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2; H is an optionally substituted C-linked 5- or 6-membered heterocyclic group; Ar is optionally substituted phenyl; and n is 0 or 1; are potent and selective cGMP PDE5 inhibitors useful in the treatment of, inter alia, male erectile dysfunction and female sexual dysfunction.

  化合物的公式（IA）和（IB）或其药理学或兽医学上可接受的盐，或者两者中的任一实体的药理学或兽医学上可接受的溶剂，其中R1是C1到C3烷基，取代为C3到C6环烷基，CONR5R6或N-连接的杂环基团；（CH2）nHet或（CH2）nAr；R2是C1到C6烷基；R3是C1到C6烷基，可选择地取代为C1到C4烷氧基；R4是SO2NR7R8；R5和R6分别独立选择自H和C1到C4烷基，可选择地取代为C1到C4烷氧基，或者与它们所连接的氮原子一起形成5-或6-成员杂环基团；R7和R8，与它们所连接的氮原子一起形成4-R10-哌嗪基团；R10是H或C1到C4烷基，可选择地取代为OH，C1到C4烷氧基或CONH2；H是可选择地取代的C-连接的5-或6-成员杂环基团；Ar是可选择地取代的苯基；n为0或1；是在治疗男性勃起功能障碍和女性性功能障碍等方面有用的有效且选择性的cGMP PDE5抑制剂。
• VERESHCHAGIN L. I.; TIXONOVA L. G.; MAKSIKOVA A. V.; GAVRILOV L. D.; GARE+, ZH. ORGAN. XIMII, 1979, 15, HO 3, 612-618
  作者：VERESHCHAGIN L. I.、 TIXONOVA L. G.、 MAKSIKOVA A. V.、 GAVRILOV L. D.、 GARE+

  DOI：——

  日期：——